SBIR/STTR Research Award
An enzyme-based assay for the detection of acetaldehyde-protein adducts
Award amount
$272,137Program and phase
SBIR · Phase IAward year
2023Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- REVEL PHARMACEUTICALS INC.
- Proposal award date
- 2023-08-01
- Contract end date
- 2024-07-31
- UEI
- RBFMLGKG8KZ3
- Solicitation number
- PA22-176
- Topic code
- 270
Research abstract
ABSTRACT
Chronic alcohol consumption is a significant issue worldwide which can lead to addiction and damage
throughout the body. The first step in alcohol metabolism is its conversion into acetaldehyde, which is a highly
reactive and toxic molecule. The formation of acetaldehyde adducts with protein and DNA is a primary
mechanism of ethanol toxicity. Acetaldehyde adducts are a direct biomarker for alcohol abuse. We intend to
develop a facile and rapid enzyme-based assay for measuring acetaldehyde-protein adducts to assess alcohol
use and alcohol-related health consequences.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Development of enzymatic tools for rapid measurement of Advanced Glycation and Lipoxidation End Product-protein adducts
- Development of advanced glycation end product (AGE)-breaking enzymes as a novel therapy for the treatment of diabetic retinopathy
- An enzyme-based assay for the detection of carboxyethyl lysine-protein adducts
- Development of advanced glycation end product (AGE)-breaking enzymes as a novel therapy for the treatment of diabetic kidney disease
- Development of enzymatic tools for rapid measurement of Advanced Glycation End Product-protein adducts
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- A Test for Heavy Alcohol Consumption in First Episode Coronary Heart Disease
- A novel and inexpensive multiplex miRNA platform for liver diseases screening
- Technology transfer of behavioral economic tasks for assessing alcohol reinforcer pathology: Development and feasibility of a commercially-available tool for clinical practice
- Development of a novel mobile application to assist in the diagnosis of Fetal Alcohol Syndrome (FAS)
- Technology transfer of behavioral economic tasks for assessing alcohol reinforcer pathology: Development and feasibility of a commercially-available tool for clinical practice
Research funding history
6 SBIR/STTR records share this UEI (2023–2025). Reported award amounts total $2,942,757. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services